Rating Change
Guggenheim analysts reiterated a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) on July 20, 2026.
reiterateNASDAQ:CLDX
Guggenheim Reiterates Buy Rating on Celldex Therapeutics, Inc. (CLDX)
Rating Change Guggenheim analysts reiterated a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) on July 20, 2026. Market Context Celldex Therapeutics, Inc.
Market Context
Celldex Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $35.58 with a market capitalization of $1.9B.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Celldex Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Celldex Therapeutics, Inc.
Among the 10 most recent ratings: 7 Buy, 1 Hold, 2 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 20, 2026 | Guggenheim | Buy | N/A |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 10, 2026 | UBS | Buy | N/A |
| May 13, 2026 | Wells Fargo | Overweight | N/A |
| May 08, 2026 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View CLDX Stock Page
Frequently Asked Questions
What does a Buy rating mean for CLDX?
A Buy rating from Guggenheim reflects the analyst's outlook on Celldex Therapeutics, Inc. (NASDAQ:CLDX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CLDX forecast page.